MAPS PBC raises $100m and rebrands to Lykos
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has announced the successful close of an oversubscribed Series A financing of more than $100 million.
It has also announced its name change to Lykos Therapeutics along with a new visual identity.
Fede Menapace, MAPS Deputy Director, stated: “For most of MAPS’ existence, the stigma associated with psychedelic compounds made it impossible to fund MAPS’ clinical research through government grants or traditional investment models. Our courageous and generous donors stepped up to advance psychedelic research, change drug policy, and shape culture.
“In a testament to Lykos’ remarkable progress in its research program, investors joining our cause are making it possible to build the commercial infrastructure required to deliver MDMA-assisted therapy to many in need, if FDA-approved.”READ MORE